Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
July 16 2024 - 1:30AM
Press Release |
Nicox appoints experienced biotech leader Damian Marron as Chair of
the Board and Marc Le Bozec as Director |
- Damian
Marron is an experienced healthcare executive, non-executive
Director/Chair and advisor
- Marc Le
Bozec is an experienced life sciences entrepreneur
with a background in finance, organization and strategic
consulting
-
Jean-François Labbe retires as Chair and member of the
Board at the completion of his term; Les Kaplan has also decided to
step down from the Board
July 16th, 2024 – release
at 7:30 am CETSophia Antipolis, FranceNicox
SA (Euronext Growth Paris: FR0013018124, ALCOX), an
international ophthalmology company, today announced the
appointment of the highly experienced healthcare executive,
non-executive Director/Chair and advisor Damian Marron as Chair of
the Board of Directors. Marc Le Bozec, an experienced life sciences
entrepreneur, is also appointed as a new Director of Nicox. Both
Damian Marron and Marc Le Bozec are independent Directors in
accordance with the criteria set out by the recommendation 3 of the
Middlenext Governance Code.Jean-François Labbe is retiring as Chair
and member of the Board, at the completion of his term. Les Kaplan
has also decided to step down from the Board. Both Jean-Francois
Labbé and Les Kaplan have contributed many years of service as
Directors of Nicox.“I am very pleased to welcome Damian Marron and
Marc Le Bozec, who both bring strong and relevant expertise in
specific areas of focus for Nicox at this stage of our development.
In particular, they will support exploring strategic options and
financing opportunities for the company alongside advising on
business development discussions on NCX 470 or our other drug
candidates.” said Gavin Spencer, Chief Executive Officer of
Nicox. “I would like to extend my thanks to Jean-François
Labbe and Les Kaplan for their long and dedicated service to Nicox.
We have appreciated their experience and guidance as Board members
and wish them all the best for the future.”“I am excited to join
Nicox at this important stage in its development. Based on its
existing revenue plus a late-stage, derisked asset, there are
multiple strategic and business development opportunities for the
Company over the next 12-18 months. I am looking forward to working
with Marc Le Bozec, Michele Garufi and Gavin Spencer on the Board
of Directors to support the Company in my new role as Chair of the
Board.” said Damian Marron, Chair of the Board of Directors
of Nicox. Damian Marron is a seasoned executive, 4-time
CEO, Chair, non-executive Board Member and company advisor with a
proven track record in value creation through public funding,
venture capital, portfolio planning, mergers and acquisitions, and
license agreements, as well as R&D collaborations. He has
extensive experience in both executive and independent
administrator roles, with a specialization in immuno-oncology,
cellular therapy, and orphan diseases. He is currently Chair of the
Board of Directors for Circio Holding ASA, Imophoron Ltd, and
Indegra Therapeutics Ltd. Marc Le Bozec is a life sciences
entrepreneur with a strong background in finance, organization and
strategic consulting. As CFO of Cellectis, he led its IPO in Paris
in 2007 and raised €120 million from 2006 to 2013. He then
redirected the company Cytoo towards human muscle research, leading
to FDA validation and becoming a key shareholder of the company.
After nine years as a professional investor, notably as fund
manager at Financière Arbevel, he resumed consulting and also
founded Neurodyx in January 2024 to advance neuro-inflammation
research. At the date of this press release, Nicox's Board of
Directors is composed as follows:
- Damian Marron, Chair of the Board
and Independent Director,
- Gavin Spencer, Chief Executive
Officer and Director,
- Michele Garufi, Co-Founder and
Director,
- Marc le Bozec, Independent
Director.
|
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470
(bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye
drop, for lowering intraocular pressure in patients with open-angle
glaucoma or ocular hypertension. Nicox generates revenue from
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch +
Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and
Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets. Nicox, headquartered in Sophia Antipolis,
France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX)
and is part of the CAC Healthcare index. For more information
www.nicox.com |
Analyst coverage |
H.C. Wainwright & Co Yi Chen New York, U.S. |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
NicoxGavin SpencerChief Executive OfficerT +33
(0)4 97 24 53 00communications@nicox.com |
Media / Investors Sophie Baumont Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
Disclaimer |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 3 of the “Rapport
Annuel 2023” which is available on Nicox’s website
(www.nicox.com).Finally, this press release may be drafted in the
French and English languages. If both versions are interpreted
differently, the French language version shall prevail. |
Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C,
Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4
97 24 53 00 |
- EN_GovernanceJuly2024_PR_FINAL